Prior Authorization Request Nevada Medicaid - OptumRx

Simponi® (golimumab)

Submit fax request to: 855-455-3303

Purpose: For a prescribing physician to request prior authorization for Simponi® (golimumab).*

Questions: If you have questions, call the OptumRx Call Center for Nevada Medicaid at 855-455-3311.

DATE OF REQUEST:					
RECIPIENT INFORMATION					
Last Name, First Name, Middle Initial: Date of Birth:					
Recipient ID:	Gender:	☐ Male ☐ Female	Phone:		
PRESCRIBING PROVIDER INFORMATION					
Name:		NPI:	Specialty:		
Phone:	Fax (req	uired):			
Person to contact regarding this request:					
DIAGNOSIS AND REQUESTED DRUG					
Name: Simponi		Strength:			
Dosage:		Duration:			
Please document the recipient's diagnosis: ☐ Ankylosing Spondylitis ☐ The recipient has had an inadequate response to NSAIDS or contraindication to treatment with an NSAID. ☐ Psoriatic Arthritis ☐ The recipient has had an inadequate response to NSAIDS or contraindication to treatment with an NSAID. ☐ Rheumatoid Arthritis ☐ Other:					
CLINICAL INFORMATION					
Check the applicable boxes to indicate each item as true for the recipient: The recipient has had a rheumatology consult. Date:					
List the medications that were tried and failed Drug Name Rease	on for Fai	•	Date(s)		
Additional clinical information (if applicable):					

PROVIDER CERTIFICATION – Prescriber's signature and date required.			
I hereby certify that this treatment is indicated and necessary and meets the guidelines fourtlined by Nevada Medicaid.	or use as		
Prescriber's Signature:	_ Date:		

This authorization request is not a guarantee of payment. Payment is contingent upon eligibility, available benefits, contractual terms, limitations, exclusions, coordination of benefits and other terms and conditions set forth by the benefit program. The information on this form and on accompanying attachments is privileged and confidential and is only for the use of the individual or entities named on this form. If the reader of this form is not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, the reader is hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If this communication is received in error, the reader shall notify sender immediately and destroy all information received.

^{*} Authorization will not be given for the use of more than one biologic at a time (combination therapy).